Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daunorubicin and Cytarabine +/- Oblimersen in Older Patients With Untreated AML
NCT00085124Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2003
- Primary completion
- Jun 2007
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 3 trial of oblimersen in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Dec 2003; status: completed.
02
Drugs
oblimersen
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00085124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085124.